SI-BONE (SIBN)
Builds iFuse implants for sacroiliac fusion, adult deformity, and pelvic trauma.
Something off on this page? Send us feedback.
Sells iFuse implants, instruments, and implantable bone products for sacropelvic surgery. Revenue is concentrated in the United States, with one reportable segment and adoption shaped by physician training, clinical evidence, reimbursement, and regulatory clearances.
Designs and commercializes titanium implants, instruments, and implantable bone products for surgical treatment of sacropelvic musculoskeletal disorders. The iFuse platform spans sacroiliac joint dysfunction, adult spinal deformity, spinopelvic fixation, and pelvic trauma applications.
Operates through one reportable segment, with revenue concentrated in the United States and a smaller international presence served through direct sales, agents, and resellers. The sales model depends on physician adoption of procedures and product families.
Competes with larger spine and orthopedics companies while building evidence around newer iFuse products. Reimbursement coverage, regulatory clearances, and clinical evidence shape how quickly hospitals and surgeons adopt the portfolio.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 4, 2026 | UBS | Reiterate | Rating: —Target: $24 | Target: $25 |
| Jul 28, 2026 | UBS | Initiate | Rating: —Target: — | Target: $24 |
| Jul 16, 2026 | Truist Financial | Target | Target: $24 | Target: $21 |
| Feb 24, 2026 | Truist Financial | Target | Target: $23 | Target: $24 |
| Dec 18, 2025 | Truist Financial | Target | Target: $20 | Target: $23 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $145.9M · Total debt $7.2M · Total assets $248.8M · Shareholders' equity $182.3M
- Revenue
- $56.0M
- Operating income
- −$4.8M
- Net income
- −$4.1M
No dividends on record.
| Institutions | 106.58% | 47.77M shares | |
|---|---|---|---|
| 173 holders · as of Jun 30, 2026 | |||
| Insiders | 4.69% | 2.10M shares | |
| 12 holders · as of Sep 3, 2026 | |||
| Adds to | 111.27% | ||
44.82M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 111.27%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
First Light Asset Management, LLCInstitution | 18.14% | 8.13M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 8.20% | 3.68M | as of Jun 30, 2026 |
Cadian Capital Management, LPInstitution | 7.47% | 3.35M | as of Jun 30, 2026 |
American Century Mutual Funds, Inc.Institution | 5.90% | 2.64M | filed May 15, 2025 |
American Century Companies IncInstitution | 5.60% | 2.51M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 1, 2026 | Jeffrey W. Dunn | director | −20,000 | $18.91 |
| Aug 24, 2026 | Anshul Maheshwari | officer: Chief Op & Financial Officer | −11,636 | $20.11 |
| Aug 24, 2026 | Laura Francis | director, officer: Chief Executive Officer | −25,972 | $20.12 |
| Aug 21, 2026 | Anshul Maheshwari | officer: Chief Op & Financial Officer | −11,228 | $20.02 |
| Aug 19, 2026 | Anshul Maheshwari | officer: Chief Op & Financial Officer | −5,747 | $19.55 |
- Globus Medical
Broad spine and musculoskeletal platform with SI pain exposure
- Medtronic
Large spine, biologics, navigation, and robotic surgery competitor
- Tenon Medical
Focused SI joint fusion peer with Catamaran and SImmetry+
- Alphatec
Spine-focused platform competing in deformity and procedural systems
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| SI-BONE | $18.83 | +2.06% | $818.2M | — | — | 3.8 | +15.2% |
| Globus Medical | $75.11 | +1.10% | $10.02B | 19.1 | 14.7 | 3.2 | +5.9% |
| Medtronic | $91.41 | −0.37% | $117.44B | 22.6 | 15.2 | 3.1 | +13.7% |
| Tenon Medical | $3.45 | −7.51% | $1.9M | — | — | 0.3 | +126.8% |
| Alphatec | $10.42 | +2.44% | $1.56B | — | 20.7 | 1.9 | +15.1% |
| Median | 20.8 | 15.2 | 2.5 | +14.4% |